Publication of Circular & Notice of GM

Summary by AI ^BETAClose X

Verici Dx Plc has published a Circular and issued a Notice of General Meeting to be held on June 22, 2026, to grant the Company authority to issue new Ordinary Shares on a non-pre-emptive basis following a fundraising announced on June 5, 2026. This action is crucial for the company's ability to raise capital and potentially fund its operations and growth initiatives in the organ transplant diagnostics sector.

Disclaimer*

Verici Dx PLC

08 June 2026

Verici Dx plc

("Verici Dx" or the "Company")

Publication of Circular

& Notice of General Meeting

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that a Circular has been published containing a notice of a general meeting to be held at the offices of Shoosmiths LLP at 1 Bow Churchyard, London, EC4M 9DQ at 11:30 a.m. on 22 June 2026 ("General Meeting").

The General Meeting is being held to ensure that the Company has sufficient authority to issue and allot new Ordinary Shares on a non-pre-emptive basis following the Fundraising announced on 5 June 2026.

The Circular and Notice of General Meeting has been posted to Shareholders and is available on the Company's website at:

https://vericidx.com/investors/documents/

Unless otherwise defined, all definitions used in this announcement will have the same meaning as described in the Circular.

Enquires:

Verici Dx plc	www.vericidx.com
Sara Barrington, CEO Julian Baines, Chairman	Via Walbrook PR

Singer Capital Markets (Nominated Adviser, Joint Broker & Joint Bookrunner)		Tel: +44 (0)20 7496 3000
Phil Davies / Jalini Kalaravy / Anastassiya Eley

Oberon Capital (Joint Broker & Joint Bookrunner)	Tel: +44 (0)20 3179 0500
Mike Seabrook / Adam Pollock / Heena Karani

Walbrook PR (Media & Investor Relations)	Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com
Alice Woodings / Rachel Broad	Mob: +44 (0)7407 804 654 / +44 (0)7747 515 393

Verici Dx

Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analysis with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence.

Operating at the intersection of laboratory and data science, Verici Dx develops complex models that answer the clinical questions that matter most with unrivaled clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive, and real-world patient populations to ensure clinical relevance and reliability. Verici Dx's lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection.

The company is UK headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit https://vericidx.com/ and follow us on LinkedIn.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END